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The Mendelian randomization (MR) approach uses genetic variants as instrumental variables to 1 
study the effect of an exposure on an outcome (1). In this way, by selecting genetic variants that 2 
serve as instrumental variables for drug effects, it can also be possible to study corresponding drug 3 
side-effects and repurposing potential (2). Such an approach has recently been applied to 4 
antihypertensive drugs, by two separate research groups independently of each other (3, 4). Here, 5 
the authors of these two papers collaboratively discuss an approach that can be used for validating 6 
instruments for such study.  7 
Both of the discussed research papers studied antihypertensive drugs using genetic variants located 8 
at the locus of the gene corresponding to their respective protein targets. The work by Gill et al. 9 
selected instruments for antihypertensive drug classes as genetic variants at the corresponding 10 
protein target’s gene, promotor or enhancer region that were also associated with systolic blood 11 
pressure (SBP) at genome-wide significance (P<5x10-8) (3). In contrast, Walker et al. selected 12 
instruments as genetic variants at the corresponding protein target’s gene that were marked as the 13 
‘best SNP’ for relation to expression of that gene in any tissue within the Genotype-Tissue Expression 14 
(GTEx) project data (5). These genetic variants were then retained for the main analysis, regardless 15 
of the tissue that they were identified in, if there was evidence that they also had an effect on SBP in 16 
two-sample MR (4).  17 
Randomized controlled trials (RCTs) represent the gold-standard for investigating drug effects, and 18 
although they can be limited by time and resource requirements, they continue to be regarded as 19 
the definitive study design for guiding clinical practice (6). Where RCT data are available on drug 20 
effects, these can be used to explore the validity of instruments selected to study the corresponding 21 
drug in MR analyses (3). When using such a strategy, it is however important to appreciate that MR 22 
and RCTs are intrinsically different approaches, and therefore the estimates that they generate are 23 
not equivalent or interchangeable. Given that MR measures the lifelong cumulative effect of genetic 24 




intervention at a discrete time point, such as in a RCT. Similarly, the population characteristics for 26 
those considered within an MR and RCT setting may not coincide. Other potential dangers of such 27 
comparison include the scenario where the MR estimates are biased due to incorporation of 28 
pleiotropic variants. Of note, bias in MR related to pleiotropy can also vary depending on the 29 
particular exposure-outcome pair under study – variants that effect one outcome through effects 30 
independent of the exposure may not necessarily do so for another. Despite these limitations, where 31 
MR analysis is being performed to investigate the clinical effects of a drug, it should generally follow 32 
that their findings are at least in-keeping with those obtained in corresponding RCTs.  33 
In the paper by Walker et al., genetic instruments for antihypertensive drug classes were identified 34 
to explore their potential for repurposing in the prevention of Alzheimer’s disease (4). For the 35 
angiotensin-converting enzyme (ACE) inhibitor, beta-adrenoceptor blocker, calcium channel blocker 36 
and thiazide-like diuretic drug classes, corresponding RCT meta-analysis estimates are available for 37 
their effect (against placebo) on risk of coronary heart disease (CHD) and stroke (7). We can compare 38 
MR estimates with corresponding RCT meta-analysis results by using the genetic instruments that 39 
Walker et al. identified for each drug classes (4), and performing two-sample inverse-variance 40 
weighted (or ratio method where only a single instrument variant is available) MR analyses for risk 41 
of CHD and stroke respectively (7). Here, we do this using publicly available genome-wide 42 
association study summary data on 60,801 CHD cases and 123,504 controls (multi-ethnic) (8), and 43 
40,585 stroke cases and 406,111 controls (European ancestry) (9). MR estimates are scaled to the 44 
effect on SBP observed in RCT meta-analyses for the respective drug class (21.1 mmHg decrease for 45 
ACE inhibitors, 9.5 mmHg decrease for beta-adrenoceptor blockers, 8.9 mmHg decrease for calcium 46 
channel blockers, and 12.6mmHg decrease for thiazide-like diuretics) (7) to allow comparison with 47 
RCT results, with the further assumption that odds ratio estimates approximate to relative risk 48 
estimates for CHD and stroke (3). The MR and RCT estimates are compared in Figure 1, and their 49 




Previous RCTs investigating the effect of treatment with antihypertensive medications have focused 51 
on dementia generally, rather than specifically considering Alzheimer’s disease (10, 11). 52 
Furthermore, these trials studied combinations of antihypertensive medication classes. While both 53 
the RCTs and the MR analyses performed by Walker et al. have focused on clinically diagnosed cases, 54 
thus introducing the possibility of misclassification, the different exposure and outcome definitions 55 
still preclude direct comparison of their results from being used to explore MR instrument validity. 56 
To summarize, evidence from RCTs provides gold-standard evidence which can be used to validate 57 
putative genetic proxies for specific drug targets. Although there are limitations to such an 58 
approach, any discordance between RCT and MR findings could be used to highlight the inclusion of 59 
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Figure legend 114 
Figure 1. Mendelian randomization estimates of antihypertensive drug effects on coronary heart 115 
disease and stroke risk, as compared to results from randomized controlled trial meta-analyses. The 116 
95% confidence intervals are provided in brackets and a log10 scale is used. 117 
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